Supplementary Data

Variable (%)[a]	Median (IQR) at baseline[b]	Median (IQR) postdose 1[c]
$CD4^+IL\text{-}2^+$	0.35 (–1.64, 2.07)	0.08 (–1.22, 1.60)
$CD4^+MIP1\beta^+$	0.10 (–1.46, 1.73)	−0.05 (–1.73, 1.01)
$CD4^+MIP1\beta^+IL2^+$	−0.12 (–0.44, 0.38)	−0.01 (–0.53, 0.23)
$CD4^+PERF^+$	−0.35 (–1.83, 1.73)	−0.49 (–2.22, 1.31)
$CD4^+TNF\text{-}\alpha^+$	−0.19 (–1.35, 2.37)	−0.21 (–0.97, 1.04)
$CD4^+PERF^+TNF\text{-}\alpha^+$	−0.08 (–0.41, 0.94)	0.04 (–0.56, 0.46)
$CD8^+IL\text{-}2^+$	0.34 (–1.22, 1.77)	0.45 (–1.01, 2.08)
$CD8^+MIP1\beta^+$	0.67 (–1.43, 2.46)	0.83 (–0.97, 2.49)
$CD8^+MIP1\beta^+IL\text{-}2^+$	0.06 (–0.91, 0.83)	0.22 (–0.25, 1.06)
$CD8^+PERF^+$	0.95 (–2.14, 4.33)	0.11 (–1.17, 1.76)
$CD8^+TNF\text{-}\alpha^+$	0.72 (–0.52, 3.63)	0.35 (–1.57, 2.48)
$CD8^+PERF^+TNF\text{-}\alpha^+$	0.38 (–0.58, 1.68)	0.10 (–0.64, 0.84)

[a]Subsets, measured by flow cytometry, are expressed as a percentage of the parent $CD4^+$ or $CD8^+$ B cell population.

[b]$N = 49$.

[c]$N = 51$.